Fly News Breaks for February 27, 2015
HPTX
Feb 27, 2015 | 07:20 EDT
Brean Capital continues to like Hyperion Therapeutics following its better than expected Q4 results. The firm cited its attractive valuation, overblown concerns surrounding its Par patent litigation, and its attractiveness as a take-out target. Brean Capital reiterated its Buy rating and $40 price target on Hyperion Therapeutics shares.
News For HPTX From the Last 2 Days
There are no results for your query HPTX